Physician profile
Ashley Bean
NPI 1285383901
$1,849.20
in general payments reported to CMS, 2019-2025
13 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $773 · 2023: $901 · 2024: $44.80 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $404.64 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $239.06 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $207.93 | 2022-2023 | Austedo, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.32 | 2022-2023 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $144.76 | 2022-2023 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Corium, LLC | $134.93 | 2022-2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $125.41 | 2022-2025 | Hetlioz, Fanapt |
| Supernus Pharmaceuticals, INC. | $110.72 | 2022-2023 | Qelbree |
| Janssen Pharmaceuticals, INC | $99.03 | 2022-2023 | Spravato |
| Noven Therapeutics, LLC | $71.16 | 2022-2023 | Secuado |
| Indivior INC. | $62.86 | 2022-2023 | Perseris |
| Tris Pharma INC | $39.76 | 2023 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $34.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Bean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.